A Study of Evacetrapib in Japanese and Non-Japanese Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2014-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to look at the effect of evacetrapib on pravastatin levels in the blood when both drugs are taken at the same time. The study will also assess how well the body handles evacetrapib and pravastatin when given at the same time.

This study has two periods in fixed order. Each participant will enroll in both periods. This study will last approximately 25 days, not including screening.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia

NCT02260648

Hypercholesterolemia

TERMINATED PHASE3

A Study of Evacetrapib in Healthy Participants

NCT01736254

Healthy Volunteers

COMPLETED PHASE1

A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia

NCT02260635

Hypercholesterolemia

TERMINATED PHASE3

A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants

NCT02156492

Healthy Volunteers

COMPLETED PHASE1

A Study of Evacetrapib in Participants With Abnormal Cholesterol

NCT02168803

Dyslipidemia

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pravastatin

Single 40 milligram (mg) oral dose of pravastatin administered on Day 1.

Group Type EXPERIMENTAL

Pravastatin

Intervention Type DRUG

Administered orally

Evacetrapib + Pravastatin

Oral doses of 130 mg evacetrapib administered once daily on Days 2 through 11, with a single oral dose of 40 mg pravastatin coadministered on Day 11.

Group Type EXPERIMENTAL

Evacetrapib

Intervention Type DRUG

Administered orally

Pravastatin

Intervention Type DRUG

Administered orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evacetrapib

Administered orally

Intervention Type DRUG

Pravastatin

Administered orally

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY2484595

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Overtly healthy participants, as determined by medical history and physical examination
* Have a body mass index of 18 to 32 kilograms per square meter (kg/m²)
* Japanese participants must be first generation Japanese

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes